Amplia gets nod for new cancer drug trial ahead of US push

smh.com.au · health
Full story

Amplia Therapeutics received ethics approval for its ACCENT-Mini pancreatic cancer trial. This approval allows the company to test the drug narmafotinib. The trial involves administering daily doses of the drug alongside chemotherapy. This occurs as the company pushes forward in the US.

Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.

Read full article → Compare